Jefferies: JD Health is expected to maintain strong growth through 2026.

Jefferies analysts stated in a report that JD Health could maintain strong growth by 2026. They believe that the company's performance will continue to exceed market expectations, driven by the introduction of new drugs, profit margin expansion from marketing services, providing chronic disease management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. They added that the company is also developing full-stack AI capabilities to improve the quality of its products. Jefferies pointed out that the management's outlook for 2026 leaves significant room for operating leverage and increase in net profit margins. Jefferies reiterated their buy rating on the stock with a target price of 88.00 Hong Kong dollars. The stock closed at 48.40 Hong Kong dollars.